Primary Objectives: - Dose Escalation Part A: To determine the maximum tolerated dose (MTD) of SAR442085 administered as a single agent in patients with relapsed or refractory multiple myeloma (RRMM), and determine the recommended Phase 2 dose (RP2D) for the subsequent Expansion Part B - Dose Expansion Part B: To assess the antitumor activity of single agent of SAR442085 at the RP2D in patients with RRMM Secondary Objectives: - To characterize the safety profile of SAR442085 - To characterize the pharmacokinetics (PK) profile of SAR442085 when administered as a single agent - To evaluate the potential immunogenicity of SAR442085 - To assess preliminary evidence of antitumor activity in the Dose Escalation Part A
This trial is currently open and accepting patients.
Phase 1
Enrollment: 78 patients (estimated)
View MoreView all clinical trial locations sorted by state.
Chapel Hill, NC
We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.
(888) 828-2206If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.
Find Nearby LocationsYou can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message